IL2 and neoplasm: The current method to generate the final TIL product for infusion uses a “rapid expansion protocol” (REP) consisting of taking TIL initially expanded from tumor fragments with IL-2 alone for 3–4 weeks and activating them with anti-CD3 in the presence of a large excess (200∶1 ratio) of irradiated PBMC feeder cells [13].